How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,333 results for

Contraceptive Selection in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Contraceptive Selection in Diabetes Mellitus

Contraceptive Selection in Diabetes Mellitus Contraceptive Selection in Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Contraceptive Selection in Diabetes Mellitus Contraceptive Selection in Diabetes Mellitus Aka: Contraceptive Selection in Diabetes Mellitus From Related Chapters II. Indications: Highly effective Contraception where pregnancy risk is too high Poorly controlled diabetes (increased risk of major ) Severe macrovascular and microvascular complications III. Management s with low-dose and less androgenic (Copper-T IUD or, based on recent data, IUD) Avoid IV. References Images: Related links

2018 FP Notebook

2. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

for the EU Market: ? Ertugliflozin 2.5 mg/metformin 850 mg FDC tablet ? Ertugliflozin 7.5 mg/metformin 850 mg FDC tablet ? Ertugliflozin 2.5 mg/metformin 1000 mg FDC tablet ? Ertugliflozin 7.5 mg/metformin 1000 mg FDC tablet. Ertugliflozin is an oral, selective inhibitor of sodium glucose co-transporter-2 (SGLT2) which inhibits renal glucose reabsorption and results in urinary glucose excretion (UGE) and reductions in plasma glucose and haemoglobin A1c (A1C) in patients with type 2 diabetes mellitus (...) Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use

2018 European Medicines Agency - EPARs

3. Adult Type 1 diabetes mellitus

Adult Type 1 diabetes mellitus Adult type 1 diabetes mellitus National Clinical Guideline No. 17 National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar June 2018This National Clinical Guideline for adults with type 1 diabetes has been developed by the Guideline Development Group, supported by the HSE National Clinical Programme for Diabetes. Part of the process of developing this guideline involved contextualising (for Ireland) the National Institute for Health and Care (...) guidance © NICE (2015) Type 1 diabetes in adults: diagnosis and management. Available from https://www.nice.org.uk/guidance/ng17 All rights reserved. Subject to Notice of rights . NICE guidance is prepared for the National Health Service in England. It is subject to regular review and updating and may be withdrawn. NICE accepts no responsibility for the use of its content in this publication. Citation text Department of Health (2018) Adult type 1 diabetes mellitus (NCEC National Clinical Guideline

2018 National Clinical Guidelines (Ireland)

4. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care.

hospitalized patients Providing medication education and diabetes survival skills to patients before hospital discharge Management of selected complications and conditions Annual comprehensive foot risk assessment Referral of patients with limb-threatening conditions Retinal examinations/screening for retinopathy Contraceptive options education and education on optimizing glycemic control in females of reproductive age Glucose variability Blood pressure Hypoglycemia/hyperglycemia Dehydration Infection (...) VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 03 Oct 2017 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted

2017 National Guideline Clearinghouse (partial archive)

5. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2017 University of Michigan Health System

6. Management of Diabetes Mellitus in Primary Care

Management of Diabetes Mellitus in Primary Care VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN PRIMARY CARE Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care (...) for specific testing and/or therapeutic interventions within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor. Version 5.0 – 2017 April 2017 Page 1 of 160 VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care April 2017 Page 2 of 160 Prepared by: The Management of Type 2 Diabetes Mellitus

2017 VA/DoD Clinical Practice Guidelines

7. To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus

To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus (CONTROL) The safety and scientific validity of this study

2018 Clinical Trials

8. Semaglutide (Ozempic) - Diabetes Mellitus

Semaglutide (Ozempic) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 14 December 2017 EMA/CHMP/715701/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ozempic International non (...) glucose lowering drugs, excl. insulins, (A10BJ06) Therapeutic indications: Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections

2018 European Medicines Agency - EPARs

9. Overweight, Obesity and Contraception

association between DMPA use and VTE. D Whilst obesity alone does not restrict the use of DMPA (UKMEC 1), DMPA use becomes a UKMEC 3 when obesity is one of multiple risk factors for CVD (e.g. smoking, diabetes and hypertension). B DMPA use appears to be associated with some weight gain, particularly in women under 18 years of age with a body mass index (BMI) =30 kg/m 2 . 13 Copyright ©Faculty of Sexual & Reproductive Healthcare 2019 FSRH guideline: Overweight, Obesity and Contraception Clinical (...) injectable contraception (UKMEC1). 1 However, when obesity is one of multiple risk factors for CVD (e.g. smoking, diabetes and hypertension), use of progestogen-only injectable contraception becomes a UKMEC 3 (the theoretical or proven risks usually outweigh the advantages of using the method). 1 The UKMEC notes that for women using NET-EN, the UKMEC categories are considered the same as for DMPA.14 Copyright ©Faculty of Sexual & Reproductive Healthcare 2019 FSRH guideline: Overweight, Obesity

2019 Faculty of Sexual & Reproductive Healthcare

10. Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus

Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our (...) use of cookies. Free Access article Share on Jump to Free Access article Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus A Scientific Statement From the American Heart Association , PhD, FAHA, Co-Chair , MD, MHS, FAHA, Co-Chair , MD, MSc , MD, FAHA , MD, MSc , PhD, RN, FAHA , MD, FAHA , MD, MPH , MD, MSCE , PhD, FAHA , MD , MD, MPH , MD, FAHA , MD, FAHA , and MD, FAHA MLIS, MS, AHIPon behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle

Full Text available with Trip Pro

2015 American Heart Association

11. Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia.

Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia. Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03676309 Recruitment Status : Completed First Posted : September 18, 2018 Last Update Posted : September 18

2018 Clinical Trials

12. Contraceptive Selection in Diabetes Mellitus

Contraceptive Selection in Diabetes Mellitus Contraceptive Selection in Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Contraceptive Selection in Diabetes Mellitus Contraceptive Selection in Diabetes Mellitus Aka: Contraceptive Selection in Diabetes Mellitus From Related Chapters II. Indications: Highly effective Contraception where pregnancy risk is too high Poorly controlled diabetes (increased risk of major ) Severe macrovascular and microvascular complications III. Management s with low-dose and less androgenic (Copper-T IUD or, based on recent data, IUD) Avoid IV. References Images: Related links

2015 FP Notebook

13. Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Mifepristone (...) in Males With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03052400 Recruitment Status : Recruiting First Posted : February 14, 2017 Last Update Posted : November 6, 2017 See Sponsor: Charles Drew

2017 Clinical Trials

14. Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03086330 Recruitment

2017 Clinical Trials

15. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents

Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies (...) with the greatest impact on clinical care. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents Kenneth C. Copeland , Janet Silverstein , Kelly R. Moore , Greg E. Prazar , Terry Raymer , Richard N. Shiffman , Shelley C. Springer , Vidhu V. Thaker , Meaghan Anderson , Stephen J. Spann , Susan K. Flinn This article has a correction. Please see: Abstract Over the past 3 decades, the prevalence of childhood obesity has increased dramatically in North America, ushering

2013 American Academy of Pediatrics

16. CPG for Diabetes Mellitus Type 1

mellitus type 1 during adolescence 178 9.4.1. Risk of diabetic decompensation during adolescence 178 9.4.2. Psychological factors in? uencing metabolic control during adolescence 179 9.4.3. Adherence to the treatment 180 9.5. Pregnancy planning 182 9.6. Complications of diabetes mellitus type 1 during pregnancy 187 9.6.1. Evolution of retinopathy during pregnancy 187 9.6.2. Evolution of nephropathy during pregnancy 188 9.7. Metabolic control during pregnancy 189 9.8. Contraception and diabetes mellitus (...) with diabetes mellitus type 1? 32. How does pregnancy affect the development of complications in diabetes mellitus type 1? 33. What should the before and during pregnancy metabolic control in women whit diabetes mellitus type 1 be? 34. What are the most recommended contraceptives in women with diabetes mellitus type 1? 35. How to adapt the clinical management of diabetes mellitus type 1 in patients whit special needs. It has been 5 years since the publication of this Clinical Practice Guideline

2012 GuiaSalud

17. A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2016 Clinical Trials

18. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. (PubMed)

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Adequate contraceptive advice is important in both women with diabetes mellitus type 1 and type 2 to reduce the risk of maternal and infant morbidity and mortality in unplanned pregnancies. A wide variety of contraceptives are available for these women. However, hormonal contraceptives might influence carbohydrate and lipid metabolism and increase micro- and macrovascular complications, so caution (...) in selecting a contraceptive method is required.To investigate whether progestogen-only, combined estrogen and progestogen or non-hormonal contraceptives differ in terms of effectiveness in preventing pregnancy, in their side effects on carbohydrate and lipid metabolism, and in long-term complications such as micro- and macrovascular disease when used in women with diabetes mellitus.The search was performed in CENTRAL, MEDLINE, EMBASE, POPLINE, CINAHL, WorldCat, ECO, ArticleFirst, the Science Citation

Full Text available with Trip Pro

2013 Cochrane database of systematic reviews (Online)

19. NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. NT-proBNP Selected (...) Huelsmann Information provided by (Responsible Party): Martin Huelsmann, Medical University of Vienna Study Details Study Description Go to Brief Summary: Purpose and rationale The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a preexisting cardiac disease. An additional aim is to demonstrate

2016 Clinical Trials

20. Post Partum Care for Gestational Diabetes Mellitus

Post Partum Care for Gestational Diabetes Mellitus KTA Evidence Summary: Postpartum Intervention for Women with History of GDM Page 1 of 19 March 2010 March 2010 – Knowledge to Action Evidence Summary What is known about postpartum intervention for women with history of GDM? Gestational diabetes mellitus (GDM) is a sentinel event in the life of a woman of reproductive age that confers risk to both mother and baby for future development of type 2 diabetes mellitus (T2D) and a host of other (...) to provide some context; these statements are not meant to address all of the evidence in existence on the subject, rather, that which is featured in this document. KTA Evidence Summary: Postpartum Intervention for Women with History of GDM Page 2 of 19 March 2010 Background According to the 2008 Canadian Diabetes Association Clinical Practice Guidelines, the prevalence of gestational diabetes mellitus (GDM) in Canada varies around 3.7% for non-Aboriginals and ranges from 8-18% in the Aboriginal

2010 OHRI Knowledge to Action

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>